Education

• Ph.D., 2018, Biostatistics, University of Florida (Advisor: Fei Zou)

Research Interest

• Personalized Medicine, Comparative Effectiveness Analysis

• Deep Learning, Machine Learning

• High-Dimensional Data, Omics Data

Publications

• Mi, X., Zou, F., and Zhu, R. (2018). Bagging and deep learning in optimal individualized treatment rules. Biometrics. [link] [R packages dnnet and ITRlearn] [Example]

• Mi, X., Tighe, P., Zou, F., Zou, B. (2018). A deep learning semiparametric regression for adjusting complex confounding structures. (In review)

• Mi, X., Zou, F., Zou, B., Hu, J. (2020). Permutation-based identification of important biomarkers for complex diseases via black-box models. (In review)

Collaboration

• Yang G. S., Mi, X., Jackson-Cook, C. K., Starkweather, A. R., Kelly, D. L., Archer, K. J., Zou, F., Lyon, D.E. (2020). Differential DNA methylation following chemotherapy for breast cancer is associated with lack of memory improvement at one year. Epigenetics

• Kirpich, A. S., Ibarra, M., Moskalenko, O., Fear, J. M., Gerken, J., Mi, X., Ashrafi, A., Morse, A. M., and McIntyre, L. M. (2018). Secimtools: a suite of metabolomics data analysis tools. BMC Bioinformatics

• Slayton, W. B., Schultz, K. R., Kairalla, J. A., Devidas, M., Mi, X., Pulsipher, M. A., Chang, B. H., Mullighan, C., Iacobucci, I., Silverman, L. B., et al. (2018). Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome–positive acute lymphoblastic leukemia: Results of children s oncology group trial aall0622. Journal of Clinical Oncology

• Ewelukwa, O., Cabrera, R., Zou, F., and Mi, X. (2016). Epidemiology of hepatocellular cancer in Florida state. American Journal of Gastroenterology

• Harrison, D. J., Parisi, M. T., Shulkin, B. L., Chi, Y.-Y., Anderson, J. R., Mi, X., Malempati, S., Mascarenhas, L., McCowage, G. B., Weigel, B., et al. (2016). 18f 2fluoro-2deoxy-d-glucose positron emission tomography (fdg-pet) response to predict event-free survival (efs) in intermediate risk (ir) or high risk (hr) rhabdomyosarcoma (rms): A report from the soft tissue sarcoma committee of the children s oncology group (cog). Journal of Clinical Oncology